


ROSENBERG'S

Rosenberg's Molecular *and* Genetic Basis of Neurological *and* Psychiatric Disease

Fifth Edition



Edited by
Roger N. Rosenberg
Juan M. Pascual



ROSENBERG'S MOLECULAR AND GENETIC
BASIS OF NEUROLOGICAL AND
PSYCHIATRIC DISEASE

FIFTH EDITION



ELSEVIER
*science &
technology books*

•• Companion Web Site:

<http://store.elsevier.com/product.jsp?&isbn=9780124105294>

Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease, 5e
Roger N. Rosenberg, Juan M. Pascual Editors

Available Resources:

- All figures from the book available in .tif, .pdf, and PowerPoint presentation formats
- Print book Table of Contents
- Abstract for each chapter
- All tables from the volume in .pdf format



ACADEMIC
PRESS

ROSENBERG'S MOLECULAR AND GENETIC BASIS OF NEUROLOGICAL AND PSYCHIATRIC DISEASE

FIFTH EDITION

Edited by

ROGER N. ROSENBERG

*The Abe (Brunky), Morris and William Zale Distinguished Chair in Neurology
Department of Neurology and Neurotherapeutics
Department of Physiology
Head, Section of Cognitive and Memory Disorders
Director, Alzheimer's Disease Center
The University of Texas Southwestern Medical Center
Dallas, TX
USA*

JUAN M. PASCUAL

*The Once Upon a Time Foundation Professorship in Pediatric Neurologic Diseases
Director, Rare Brain Disorders Program
Department of Neurology and Neurotherapeutics
Department of Physiology
Department of Pediatrics
Eugene McDermott Center for Human Growth & Development/Center for Human Genetics
Division of Pediatric Neurology
The University of Texas Southwestern Medical Center
Dallas, TX
USA*



AMSTERDAM • BOSTON • HEIDELBERG • LONDON
NEW YORK • OXFORD • PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO
Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier
32 Jamestown Road, London NW1 7BY, UK
225 Wyman Street, Waltham, MA 02451, USA
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA

Fifth edition

Copyright © 2015 Elsevier Inc. All rights reserved
4th Edition © 2008 by Lippincott Williams & Wilkins, a Wolters Kluwer business

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: permissions@elsevier.com. Alternatively, visit the Science and Technology Books website at www.elsevierdirect.com/rights for further information

Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloguing-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN: 978-0-12-410529-4

For information on all Academic Press publications
visit our website at www.store.elsevier.com

Typeset by SPI

Printed and bound in United States of America

15 16 17 18 19 10 9 8 7 6 5 4 3 2 1



Dedications

We dedicate this text to our colleagues, who, by perseverance and dedication, have provided essential new scientific knowledge about the molecular and genetic basis of neurologic and psychiatric disorders, and, in so doing, have conceptualized important insights into disease causation and therapies for the future.

Roger N. Rosenberg and Juan M. Pascual

I wish to dedicate this work to my parents, Cora and Sol Rosenberg, and to my wife, Adrienne. They have been an inspiration to me and have provided me with their care and love to maintain my focus and resilience throughout my life and career, for which I will forever be grateful.

Roger N. Rosenberg

Juan M. Pascual dedicates this work to the memory of his father, Juan Pascual Toledo, magister, who traversed his life and ours loyal, unswerving, and serene, and awaits:

*“Venisti tandem, tuaque exspectata parenti
vicit iter durum pietas?
datur ora tueri,
nate, tua et notas audire et reddere voces?”*

This page intentionally left blank

Contents

| | |
|------------------------------------|--------|
| Preface to the Fifth Edition | xxxiii |
| Contributors | xxxv |

I GENERAL CONCEPTS AND TOOLS

1. Mendelian, Non-Mendelian, Multigenic Inheritance, and Epigenetics

TAMAR HAREL, DAVUT PEHLIVAN, C. THOMAS CASKEY, AND JAMES R. LUPSKI

| | |
|---|----|
| Introduction..... | 3 |
| Mendelian Traits..... | 4 |
| Repeat Expansion Disorders | 8 |
| Non-Mendelian Inheritance | 9 |
| Chromosomal and Genomic Disorders | 11 |
| Multigenic Inheritance..... | 17 |
| Complex Traits..... | 18 |
| Epigenetics | 20 |
| The Human Genome: High-Throughput Technologies..... | 22 |
| Conclusions..... | 23 |
| References | 24 |

2. Genotype–Phenotype Correlations

THOMAS D. BIRD AND MARIE Y. DAVIS

| | |
|--|----|
| Introduction..... | 29 |
| Single Phenotype: Multiple Genes..... | 29 |
| Single Gene: Multiple Phenotypes..... | 31 |
| Neuronal/Cellular Selective Vulnerability..... | 32 |
| Highly Variable Systemic Phenotypes..... | 33 |
| Penetrance and Age of Onset..... | 35 |
| Conclusion and Future Directions..... | 36 |
| References | 37 |

3. Immunogenetics of Neurological Disease

RAMYIADARSINI I. ELANGOVAN, SREERAM V. RAMAGOPALAN, AND DAVID A. DYMENT

| | |
|---|----|
| Introduction..... | 39 |
| Epidemiological Evidence for Genetic Susceptibility | 39 |
| Genetics of MS: Family-Based Investigations | 40 |
| The Role of Major Histocompatibility Complex Genes..... | 41 |
| Other Immune-Related Genes | 43 |
| The Environment and Immune-Related Genes..... | 47 |
| Conclusion..... | 47 |
| References | 48 |

4. Pharmacogenomic Approaches to the Treatment of Sporadic Alzheimer Disease using Cholinomimetic Agents

JUDES POIRIER, JUSTIN MIRON, AND CYNTHIA PICARD

| | |
|--|----|
| Introduction..... | 51 |
| Genetic Risk Factors and Sporadic Alzheimer Disease..... | 51 |
| Genetic Risk Factors, Cholinergic Dysfunction, and Alzheimer Disease..... | 53 |
| ApoE4 and Cholinomimetic Drugs in Alzheimer Disease..... | 53 |
| Experimental Drugs and their Relationship to the ApoE4 Allele..... | 57 |
| Acetylcholinesterase and Butyrylcholinesterase Genetic Variants in Dementia..... | 58 |
| Acknowledgements..... | 60 |
| References..... | 60 |

5. Application of Mouse Genetics to Human Disease: Generation and Analysis of Mouse Models

TERESA M. GUNN AND BRENDA CANINE

| | |
|--|----|
| Introduction..... | 63 |
| Creating Mouse Models..... | 64 |
| Phenotypic Analysis of Mouse Models..... | 71 |
| Summary..... | 74 |
| References..... | 74 |

6. DNA Sequencing and Other Methods of Exonic and Genomic Analyses

JUN MITSUI, HIROYUKI ISHIURA, AND SHOJI TSUJI

| | |
|---|----|
| DNA Sequencing Technologies..... | 77 |
| NGS for Elucidating Mendelian-Trait Diseases..... | 79 |
| NGS for Elucidating Molecular Bases of Diseases with Mendelian Trait..... | 81 |
| NGS for Elucidating Molecular Bases of Complex-Trait Diseases..... | 81 |
| NGS for Clinical Sequencing..... | 82 |
| Other Methods of Exonic and Genomic Analysis..... | 82 |
| References..... | 84 |

7. Association, Cause and Causal Association: Means, Methods and Measures

WALTER A. KUKULL

| | |
|---|----|
| Learning from Infectious Disease..... | 87 |
| Causal “Guidelines” and Observational vs. Experimental Designs..... | 88 |
| The Future?..... | 91 |
| References..... | 92 |

8. Gene Therapy for Neurological Disease

THEODORE FRIEDMANN

| | |
|--|----|
| Introduction and Recent Progress..... | 95 |
| Progress in Gene Therapy for Neurodevelopmental and Neurodegenerative Disease..... | 96 |
| References..... | 99 |

9. Direct Induction of Neural Stem Cells from Somatic Cells

WADO AKAMATSU AND HIDEYUKI OKANO

| | |
|--|-----|
| Introduction..... | 103 |
| Direct Induction of NSCs from Somatic Cells..... | 104 |
| Comparison of Direct Induction into NSCs..... | 105 |
| Direct Induction of Neural Stem Cell in Regenerative Medicine..... | 105 |
| References..... | 106 |

10. Neuroimaging in Dementias

PRASHANTHI VEMURI, MELISSA E. MURRAY, AND CLIFFORD R. JACK, JR.

| | |
|---------------------------------|-----|
| Introduction..... | 107 |
| Neuroimaging Technologies | 107 |
| Alzheimer Disease..... | 108 |
| Dementia with Lewy Bodies | 111 |
| Frontotemporal Dementia | 113 |
| Imaging Vascular Disease..... | 115 |
| References | 116 |

11. Cognitive Enhancers and Mental Impairment: Emerging Ethical Issues

FABRICE JOTTERAND, JENNIFER L. McCURDY, AND BERNICE ELGER

| | |
|--|-----|
| Introduction..... | 119 |
| Neuroethics in Context..... | 120 |
| Therapy–Enhancement: A False Dichotomy..... | 120 |
| Cognitive Enhancers | 121 |
| Personal Identity and Mental Impairments..... | 122 |
| Identity and Enhancement-2..... | 123 |
| Ethical Implications for Persons with Mental Impairment..... | 124 |
| Recommendations | 124 |
| Conclusion..... | 125 |
| References | 125 |

12. Genetic Counseling

WENDY R. UHLMANN

| | |
|---|-----|
| Genetic Counseling Defined and Providers | 127 |
| Which Patients Could Benefit from Genetic Counseling? | 127 |
| Components of Genetic Counseling and Case Preparation | 128 |
| Risk Assessment..... | 129 |
| Counseling and Education About the Genetic Condition..... | 130 |
| Genetic Testing..... | 130 |
| Insurance Considerations and Implications | 131 |
| Test Interpretation | 131 |
| Ethical Issues | 132 |
| Identifying Supportive Resources for Patients | 132 |
| Conclusions..... | 132 |
| References | 133 |

II NEUROLOGIC DISEASES

13. Cerebral Malformations

WILLIAM D. GRAF AND SHIHUI YU

| | |
|------------------------------|-----|
| Clinical Features | 137 |
| Molecular Genetics..... | 142 |
| Disease Mechanisms | 144 |
| Differential Diagnosis | 147 |
| Testing..... | 148 |
| Management | 149 |
| References | 149 |

14. Global Developmental Delay and Intellectual Disability

MYRIAM SROUR AND MICHAEL SHEVELL

| | |
|-------------------------------|-----|
| Clinical Features | 151 |
| Diagnosis | 152 |
| Evaluation and Testing | 153 |
| Microdeletion Syndromes..... | 154 |
| Monogenetic Causes of ID..... | 155 |
| X-Linked ID..... | 156 |
| Autosomal Dominant ID..... | 157 |
| Autosomal Recessive ID..... | 157 |
| Disease Mechanisms | 157 |
| Management | 158 |
| References | 159 |

15. Down Syndrome

ALLISON CABAN-HOLT, ELIZABETH HEAD, AND FREDERICK SCHMITT

| | |
|-----------------------------------|-----|
| Introduction..... | 163 |
| Hallmarks of Down Syndrome..... | 163 |
| Inheritance..... | 163 |
| Diagnosis and Testing | 164 |
| Early Intervention/Treatment..... | 164 |
| Prevalence..... | 165 |
| Disease Evolution..... | 165 |
| Pathophysiology..... | 168 |
| Conclusions..... | 168 |
| Acknowledgements..... | 168 |
| References | 169 |

16. An Overview of Rett Syndrome

KRISTEN L. SZABLA AND LISA M. MONTEGGIA

| | |
|--------------------------|-----|
| Introduction..... | 171 |
| Clinical Features | 172 |
| Molecular Genetics..... | 173 |
| Disease Mechanisms | 174 |
| Management | 178 |
| References | 179 |

17. Fragile X-Associated Disorders

REYMUNDO LOZANO, EMMA B. HARE, AND RANDI J. HAGERMAN

| | |
|--|-----|
| Introduction..... | 183 |
| Disease Characteristics | 183 |
| Clinical Diagnosis..... | 185 |
| Historical Overview..... | 186 |
| Mode of Inheritance and Prevalence | 186 |
| Molecular Genetics..... | 188 |
| Disease Mechanisms | 189 |
| Differential Diagnosis | 190 |
| Testing..... | 190 |
| Management | 190 |
| Acknowledgements..... | 192 |
| Conflicts..... | 192 |
| References | 192 |

18. Autism Spectrum Disorders: Clinical Considerations

PATRICIA EVANS, SAILAJA GOLLA, AND MARY ANN MORRIS

| | |
|---|-----|
| Introduction..... | 197 |
| Overview..... | 197 |
| Clinical Features and Diagnostic Evaluation | 198 |
| Therapeutic Approaches | 200 |
| References | 204 |

19. Metabolic and Genetic Causes of Autism

SAILAJA GOLLA AND PATRICIA EVANS

| | |
|------------------------------------|-----|
| Introduction..... | 209 |
| Fragile X Syndrome (FRX)..... | 209 |
| Neurocutaneous Syndromes | 212 |
| Phenylketonuria..... | 212 |
| Angelman Syndrome..... | 212 |
| Rett Syndrome..... | 212 |
| Smith–Lemli–Opitz Syndrome..... | 212 |
| <i>In Utero</i> Drug Exposure..... | 213 |
| Second-Hit Theory..... | 213 |
| Summary..... | 213 |
| References..... | 214 |

20. Angelman Syndrome

CHARLES A. WILLIAMS AND JENNIFER M. MUELLER

| | |
|-----------------------------|-----|
| Introduction..... | 219 |
| Clinical Features..... | 219 |
| Natural History..... | 220 |
| Molecular Genetics..... | 221 |
| Disease Mechanisms..... | 223 |
| Differential Diagnosis..... | 224 |
| Testing..... | 224 |
| Management..... | 225 |
| References..... | 226 |

21. Prion Diseases

JAMES A. MASTRIANNI

| | |
|--|-----|
| Introduction..... | 229 |
| Origins of Discovery | 229 |
| Epidemiology..... | 230 |
| Pathologic Features of Prion Diseases..... | 230 |
| Genetics of Prion Diseases..... | 231 |
| Cellular Prion Protein Biology | 233 |
| Prion Biology | 234 |
| Prion-Related Proteins..... | 241 |
| Human Prion Disease Subtypes..... | 241 |
| Diagnostic Studies | 245 |
| Treatment..... | 246 |
| References..... | 246 |

III NEUROMETABOLIC DISORDERS

MITOCHONDRIAL DISORDERS

22. The Mitochondrial Genome

ERIC A. SCHON

| | |
|-------------------------------------|-----|
| Mitochondrial Origins | 259 |
| Genome Organization | 259 |
| Mitochondrial Inheritance | 262 |
| Segregation and Heteroplasmy | 262 |
| Mitochondrial DNA Replication | 263 |
| Transcription | 265 |
| Translation | 266 |
| Importation | 267 |
| Acknowledgements | 268 |
| References | 268 |

23. Mitochondrial Disorders Due to Mutations in the Mitochondrial Genome

SALVATORE DIMAURO AND CARMEN PARADAS

| | |
|----------------------------------|-----|
| Introduction | 271 |
| Clinical Features | 271 |
| Diagnostic Evaluation | 274 |
| Pathology | 275 |
| Biochemical Findings | 276 |
| Molecular Genetic Findings | 277 |
| Animal Models | 279 |
| Therapy | 280 |
| Conclusion | 280 |
| Acknowledgements | 280 |
| References | 280 |

24. Mitochondrial Disorders Due to Mutations in the Nuclear Genome

PATRICK F. CHINNERY

| | |
|---|-----|
| Clinical Overview and History | 283 |
| Molecular Genetics and Disease Mechanisms | 288 |
| Testing | 288 |
| Management | 288 |
| References | 289 |

25. Pyruvate Dehydrogenase, Pyruvate Carboxylase, Krebs Cycle and Mitochondrial Transport Disorders

MIREIA TONDO, ISAAC MARIN-VALENCIA, QIAN MA, AND JUAN M. PASCUAL

| | |
|---|-----|
| Introduction | 291 |
| Pyruvate Dehydrogenase Deficiency | 291 |
| Pyruvate Carboxylase Deficiency | 292 |
| Disorders of the Krebs Cycle | 294 |
| Mitochondrial Transporter Disorders | 295 |
| Acknowledgements | 296 |
| References | 296 |

LYSOSOMAL DISORDERS

26. Gaucher Disease: Neuronopathic Forms

RAPHAEL SCHIFFMANN

| | |
|-----------------------------|-----|
| Introduction..... | 301 |
| Clinical Features..... | 301 |
| Molecular Genetics..... | 304 |
| Pathophysiology..... | 304 |
| Differential Diagnosis..... | 307 |
| Diagnostic Testing..... | 307 |
| Management..... | 308 |
| References..... | 309 |

27. The Niemann–Pick Diseases

EDWARD H. SCHUCHMAN AND ROBERT J. DESNICK

| | |
|--|-----|
| Introduction..... | 313 |
| Clinical Features and Diagnostic Evaluation..... | 313 |
| Radiologic and Neurophysiologic Studies..... | 314 |
| Pathology..... | 314 |
| Biochemical Findings..... | 314 |
| Brain Immunochemical Findings..... | 315 |
| Mechanism of Disease..... | 315 |
| Molecular Genetics..... | 315 |
| Animal Models..... | 316 |
| Therapy..... | 317 |
| Conclusions..... | 318 |
| References..... | 319 |

28. G_{M2}-Gangliosidoses

GREGORY M. PASTORES AND GUSTAVO H.B. MAEGAWA

| | |
|------------------------------|-----|
| Introduction..... | 321 |
| Clinical Features..... | 322 |
| Diagnostic Confirmation..... | 323 |
| Molecular Genetics..... | 324 |
| Disease Mechanisms..... | 325 |
| Imaging..... | 326 |
| Differential Diagnosis..... | 326 |
| Management..... | 327 |
| References..... | 328 |

29. Metachromatic Leukodystrophy and Multiple Sulfatase Deficiency

FLORIAN S. EICHLER

| | |
|-----------------------------|-----|
| Introduction..... | 331 |
| Clinical Features..... | 332 |
| Molecular Genetics..... | 333 |
| Disease Mechanisms..... | 333 |
| Differential Diagnosis..... | 333 |
| Testing..... | 334 |
| Management..... | 334 |
| References..... | 336 |

30. Krabbe Disease: Globoid Cell Leukodystrophy

DAVID A. WENGER AND PAOLA LUZI

| | |
|------------------------------|-----|
| Introduction..... | 337 |
| Clinical Features | 338 |
| Molecular Genetics..... | 338 |
| Disease Mechanisms | 340 |
| Current Research..... | 342 |
| Differential Diagnosis | 342 |
| Testing..... | 343 |
| Management | 344 |
| Acknowledgements..... | 345 |
| References | 345 |

31. The Mucopolysaccharidoses

REUBEN MATALON, KIMBERLEE MICHALS MATALON, AND GEETHA L. RADHAKRISHNAN

| | |
|---|-----|
| Introduction..... | 347 |
| History..... | 347 |
| Manifestations of the Mucopolysaccharidoses | 348 |
| Therapy for the Mucopolysaccharidoses | 359 |
| References | 360 |

32. The Mucolipidoses

REUBEN MATALON AND KIMBERLEE MICHALS MATALON

| | |
|---|-----|
| Introduction..... | 365 |
| Manifestations of the Mucolipidoses | 365 |
| References | 367 |

33. Disorders of Glycoprotein Degradation: Sialidosis, Fucosidosis, α -Mannosidosis, β -Mannosidosis, and Aspartylglycosaminuria

WILLIAM G. JOHNSON

| | |
|---|-----|
| Introduction..... | 369 |
| Biosynthesis and Biodegradation of Glycoproteins..... | 370 |
| Sialidosis | 371 |
| Fucosidosis..... | 374 |
| α -Mannosidosis..... | 376 |
| β -Mannosidosis..... | 379 |
| Aspartylglycosaminuria..... | 380 |
| References | 382 |

34. β -Galactosidase Deficiency: G_{M1} Gangliosidosis, Morquio B Disease, and Galactosialidosis

WILLIAM G. JOHNSON

| | |
|---|-----|
| Introduction..... | 385 |
| G_{M1} Gangliosidosis and Morquio B Disease | 385 |
| G_{M1} Gangliosidosis..... | 386 |
| Morquio B Disease | 387 |
| Galactosialidosis | 390 |
| Animal Models | 392 |
| Status and Future Possibility of Therapy..... | 392 |
| Acknowledgement..... | 393 |
| References | 393 |

35. Acid Ceramidase Deficiency: Farber Lipogranulomatosis and Spinal Muscular Atrophy Associated with Progressive Myoclonic Epilepsy

MICHAEL BECK, HUGO W. MOSER, AND KONRAD SANDHOFF

| | |
|---------------------------------------|-----|
| Introduction..... | 395 |
| Clinical Picture..... | 395 |
| Diagnosis..... | 397 |
| Pathology..... | 398 |
| Clinical Genetics..... | 399 |
| Molecular Genetics..... | 399 |
| Animal Models..... | 399 |
| Therapy..... | 399 |
| Conclusion and Future Directions..... | 400 |
| References..... | 400 |

36. Wolman Disease

ISAAC MARIN-VALENCIA AND JUAN M. PASCUAL

| | |
|--------------------------------|-----|
| Clinical Features..... | 403 |
| Molecular Genetics..... | 403 |
| Disease Mechanisms..... | 404 |
| Differential Diagnosis..... | 405 |
| Testing..... | 405 |
| Therapeutic Interventions..... | 406 |
| References..... | 408 |

37. Lysosomal Membrane Disorders: LAMP-2 Deficiency

KAZUMA SUGIE AND ICHIZO NISHINO

| | |
|------------------------|-----|
| Introduction..... | 411 |
| Danon Disease..... | 411 |
| Clinical Features..... | 411 |
| Management..... | 415 |
| References..... | 416 |

38. Fabry Disease: α -Galactosidase A Deficiency

ROBERT J. DESNICK

| | |
|--|-----|
| Introduction..... | 419 |
| Clinical Features and Diagnostic Evaluation..... | 419 |
| Diagnostic Evaluation..... | 422 |
| Pathology..... | 423 |
| Biochemistry..... | 423 |
| Molecular Genetics..... | 424 |
| Treatment..... | 424 |
| Summary..... | 427 |
| Acknowledgements..... | 427 |
| References..... | 427 |

39. Schindler Disease: Deficient-N-Acetylgalactosaminidase Activity

DETLEV SCHINDLER AND ROBERT J. DESNICK

| | |
|---|-----|
| Introduction..... | 431 |
| Clinical Features and Diagnostic Results..... | 431 |

| | |
|-----------------------------------|-----|
| Diagnostic Evaluation..... | 434 |
| Pathology | 435 |
| Biochemistry | 436 |
| Molecular Genetics..... | 436 |
| Relation to Other Gene Loci | 437 |
| Animal Model..... | 437 |
| Therapy..... | 438 |
| Future Research Directions..... | 438 |
| Acknowledgements..... | 438 |
| References | 438 |

METAL METABOLISM DISORDERS

40. Wilson Disease

GOLDER N. WILSON

| | |
|--------------------------|-----|
| Summary | 443 |
| Clinical Features | 445 |
| Natural History | 446 |
| Molecular Genetics..... | 447 |
| Disease Mechanisms | 448 |
| Testing..... | 449 |
| Management | 450 |
| References | 452 |

41. Menkes Disease and Other *ATP7A* Disorders

JUAN M. PASCUAL AND JOHN H. MENKES

| | |
|---|-----|
| Introduction..... | 455 |
| Menkes Disease..... | 455 |
| Occipital Horn Syndrome | 459 |
| <i>ATP7A</i> -Related Distal Motor Neuropathy | 460 |
| Mode of Inheritance of <i>ATP7A</i> -Related Disorders..... | 461 |
| Acknowledgements..... | 461 |
| References | 461 |

42. Neurodegeneration with Brain Iron Accumulation

SUSANNE A. SCHNEIDER

| | |
|--|-----|
| Introduction and Clinical Features | 463 |
| Natural History | 464 |
| Molecular Genetics and Genotype–Phenotype Correlations | 465 |
| Disease Mechanisms | 466 |
| Investigation | 468 |
| Differential Diagnosis | 469 |
| Management | 470 |
| References | 470 |

43. Pantothenate Kinase-Associated Neurodegeneration

MICHAEL C. KRUER

| | |
|--------------------------------|-----|
| Introduction..... | 473 |
| Clinical Features | 473 |
| Laboratory Findings | 475 |
| Neuroimaging Features | 475 |
| Definitive Diagnosis..... | 476 |
| Neuropathologic Findings | 476 |

| | |
|--|-----|
| Current Treatment Strategies | 477 |
| Biological Basis of Disease | 477 |
| Animal Models | 478 |
| Burgeoning Therapies and Rationale | 479 |
| Conclusions and Future Directions | 479 |
| References | 480 |

44. Disorders of Manganese Transport

ISAAC MARIN-VALENCIA

| | |
|---|-----|
| Introduction | 483 |
| Clinical Features | 483 |
| Molecular Genetics | 485 |
| Physiology and Disease Mechanisms | 485 |
| Differential Diagnosis | 487 |
| Testing | 490 |
| Management | 490 |
| References | 491 |

45. Aceruloplasminemia

SATOSHI KONO AND HIROAKI MIYAJIMA

| | |
|------------------------------|-----|
| Clinical Features | 495 |
| Laboratory Testing | 496 |
| Molecular Genetics | 498 |
| Disease Mechanisms | 500 |
| Differential Diagnosis | 503 |
| Management | 503 |
| References | 504 |

VITAMIN DISORDERS

46. Genetic and Dietary Influences on Lifespan

YIAN GU, NICOLE SCHUPF, AND RICHARD MAYEUX

| | |
|---|-----|
| Introduction | 509 |
| Hypothesis of Longevity and Senescence | 509 |
| Caloric Intake, α -Tocopherol, and Other Dietary Factors | 510 |
| Genetics of Aging and Lifespan | 512 |
| Conclusion | 516 |
| Acknowledgements | 516 |
| References | 516 |
| Further Reading | 520 |

47. Vitamins: Cobalamin and Folate

DAVID WATKINS, CHARLES P. VENDITTI, AND DAVID S. ROSENBLATT

| | |
|------------------|-----|
| Cobalamin | 521 |
| Folate | 525 |
| References | 527 |

48. Disorders of Biotin Metabolism

SARA ELREFAI AND BARRY WOLF

| | |
|---|-----|
| Biotin | 531 |
| Holocarboxylase Synthetase Deficiency | 531 |
| Biotinidase Deficiency | 534 |

| | |
|---|-----|
| Biotin-Responsive Basal Ganglia Disease | 537 |
| Conclusion | 537 |
| References | 538 |

49. Disorders of Pyridoxine Metabolism

CLARA VAN KARNEBEEK AND SIDNEY M. GOSPE, JR.

| | |
|--|-----|
| Introduction | 541 |
| Clinical Features | 541 |
| Natural History | 542 |
| Molecular Genetics: ATQ | 543 |
| Molecular Genetics: PNPO and TNSALP | 545 |
| Disease Mechanisms and Pathophysiology | 545 |
| Differential Diagnosis | 546 |
| Testing | 546 |
| Management | 548 |
| Acknowledgements | 552 |
| References | 552 |

LIPID METABOLISM DISORDERS

50. Disorders of Lipid Metabolism

STEFANO DI DONATO AND FRANCO TARONI

| | |
|--|-----|
| Introduction | 559 |
| Pathophysiology | 559 |
| Clinical Features | 564 |
| Defects of Mitochondrial Fatty-Acid Oxidation | 566 |
| Other Disorders of Fatty-Acid β -Oxidation | 572 |
| Acknowledgements | 573 |
| References | 573 |

51. Lipoprotein Disorders

MARY J. MALLOY AND JOHN P. KANE

| | |
|---|-----|
| Introduction | 577 |
| Lipoprotein Structure and Metabolism | 578 |
| Disorders of Lipoproteins Containing Apoprotein B | 581 |
| Disorders of High-Density Lipoproteins | 584 |
| Conclusion | 586 |
| Addendum | 586 |
| References | 586 |

52. Cerebrotendinous Xanthomatosis

VLADIMIR M. BERGINER, GERALD SALEN, AND SHAIENDRA B. PATEL

| | |
|--------------------------|-----|
| Introduction | 589 |
| Clinical Features | 589 |
| Molecular Genetics | 593 |
| Disease Mechanisms | 595 |
| Diagnosis | 596 |
| Management | 596 |
| References | 597 |

OTHER METABOLIC DISORDERS

53. Organic Acid Disorders

MARGRETTA REED SEASHORE

| | |
|-----------------------------|-----|
| Introduction..... | 601 |
| Clinical Features..... | 602 |
| Natural History..... | 603 |
| Pathophysiology..... | 603 |
| Differential Diagnosis..... | 604 |
| Molecular Genetics..... | 604 |
| Testing..... | 604 |
| Management..... | 606 |
| References..... | 606 |
| Selected Reading..... | 606 |

54. Glycogen Storage Diseases

SALVATORE DIMAURO AND HASAN ORHAN AKMAN

| | |
|---------------------------------|-----|
| Introduction..... | 607 |
| Clinical Features..... | 607 |
| Diagnostic Evaluation..... | 609 |
| Pathology..... | 610 |
| Biochemical Findings..... | 611 |
| Molecular Genetic Findings..... | 611 |
| Animal Models..... | 612 |
| Therapy..... | 612 |
| Conclusion..... | 613 |
| Acknowledgement..... | 613 |
| References..... | 613 |

55. Disorders of Galactose Metabolism

GERARD T. BERRY

| | |
|--|-----|
| Introduction..... | 615 |
| Classic Galactosemia..... | 615 |
| Uridine Diphosphate-Galactose 4'-Epimerase Deficiency..... | 620 |
| Galactokinase Deficiency..... | 621 |
| Fanconi-Bickel Syndrome..... | 622 |
| Portosystemic Venous Shunting and Hepatic Arteriovenous Malformations..... | 622 |
| References..... | 622 |

56. Inborn Errors of Amino Acid Metabolism

WILLIAM L. NYHAN AND RICHARD HAAS

| | |
|---|-----|
| Phenylketonuria and Disorders of Bipterin Metabolism..... | 627 |
| Hepatorenal Tyrosinemia..... | 628 |
| Nonketotic Hyperglycinemia..... | 629 |
| Maple Syrup Urine Disease..... | 630 |
| References..... | 631 |

57. Urea Cycle Disorders

NICHOLAS AH MEW, MARIA BELEN PAPPAS, AND ANDREA L. GROPMAN

| | |
|------------------------|-----|
| Introduction..... | 633 |
| Clinical Features..... | 633 |
| Natural History..... | 635 |

| | |
|--|-----|
| Molecular Genetics..... | 636 |
| Expression of Urea Cycle Enzymes and Nitrogen Metabolism | 638 |
| Disease Mechanisms/Pathophysiology..... | 638 |
| Differential Diagnosis | 640 |
| Testing..... | 640 |
| Management | 641 |
| Current Research..... | 642 |
| References | 643 |

58. Glucose Transporter Type I Deficiency and Other Glucose Flux Disorders

JUAN M. PASCUAL, DONG WANG, AND DARRYL C. DE VIVO

| | |
|---|-----|
| Overview of Glucose Transport | 649 |
| Clinical Features | 649 |
| Molecular Genetics of GLUT1 Deficiency | 651 |
| Disease Mechanisms in GLUT1 Deficiency..... | 654 |
| Animal Models of GLUT1 Deficiency..... | 655 |
| Differential Diagnosis of GLUT1 Deficiency..... | 656 |
| Testing for GLUT1 Deficiency..... | 657 |
| Management of GLUT1 Deficiency..... | 657 |
| Acknowledgements..... | 659 |
| References | 659 |

59. Maple Syrup Urine Disease: Clinical and Therapeutic Considerations

DAVID T. CHUANG, R. MAX WYNN, RODY P. COX, AND JACINTA L. CHUANG

| | |
|---|-----|
| Introduction..... | 663 |
| Clinical Presentation of Classic MSUD..... | 663 |
| Neuropathology of MSUD | 664 |
| Variant Types of MSUD | 664 |
| Genetics and Prevalence | 665 |
| Component Enzymes and Macromolecular Organization of BCKDC..... | 665 |
| The Thiamine-Responsive Phenotype is Linked to the Presence of Mutant E2 Proteins | 667 |
| Animal Models for Classic and Intermediate MSUD..... | 667 |
| Treatments of MSUD | 668 |
| Concluding Remarks | 669 |
| Acknowledgements..... | 670 |
| References | 670 |

60. Congenital Disorders of N-Linked Glycosylation

MARC C. PATTERSON

| | |
|---|-----|
| Introduction..... | 673 |
| Clinical Features and Diagnostic Evaluation | 674 |
| Pathology | 679 |
| Molecular Genetic Data | 680 |
| Animal Models | 681 |
| Therapy..... | 681 |
| Conclusion | 681 |
| References | 682 |

61. Disorders of Glutathione Metabolism

KOJI AOYAMA AND TOSHIO NAKAKI

| | |
|--|-----|
| Introduction..... | 687 |
| GSH and the γ -Glutamyl Cycle | 687 |
| Disorders of Enzymes in the γ -Glutamyl Cycle | 688 |

| | |
|---|-----|
| Excitatory Amino Acid Transporters (EAATs)..... | 689 |
| Disorders of EAAC1 Leading to GSH Depletion | 690 |
| Neurodegenerative Diseases Leading to GSH Depletion | 690 |
| Conclusions..... | 692 |
| References | 692 |

62. Canavan Disease

REUBEN MATALON AND KIMBERLEE MICHALS MATALON

| | |
|-------------------------------------|-----|
| Introduction..... | 695 |
| History..... | 695 |
| Basic Defect | 695 |
| Clinical Features | 696 |
| Diagnosis | 696 |
| Differential Diagnosis | 697 |
| Epidemiology..... | 697 |
| Molecular Basis | 697 |
| Prevention/Prenatal Diagnosis | 698 |
| Management | 698 |
| Therapy | 698 |
| References | 699 |

63. Neurotransmitter Disorders

ÀNGELS GARCÍA-CAZORLA AND RAFAEL ARTUCH

| | |
|---|-----|
| Introduction..... | 703 |
| Disorders of Monoamines | 704 |
| Disorders of GABA..... | 708 |
| Pyridoxine-Responsive Epilepsy | 710 |
| Pyridoxamine 5'-Phosphate Oxidase Deficiency..... | 710 |
| References | 711 |

64. Peroxisomal Disorders

GERALD V. RAYMOND

| | |
|---|-----|
| Introduction..... | 713 |
| Disorders of Peroxisome Biogenesis..... | 713 |
| Peroxisomal Disorders Due to Defects in Single Peroxisomal Enzymes..... | 717 |
| Other Peroxisomal Single-Enzyme Defects | 722 |
| References | 722 |

65. Disorders of Purine Metabolism

WILLIAM L. NYHAN

| | |
|--|-----|
| Lesch-Nyhan Disease..... | 725 |
| Phosphoribosylpyrophosphate (PRPP) Synthetase Abnormalities..... | 729 |
| References | 730 |

66. The Porphyrrias

D. MONTGOMERY BISSELL

| | |
|---|-----|
| Introduction..... | 731 |
| Porphyria: Clinical Aspects | 733 |
| Diagnosis | 735 |
| Pathogenesis of Neurologic Symptoms..... | 738 |
| Chemical and Physiologic Inducers of Acute Porphyria..... | 739 |
| Molecular Genetics..... | 740 |

| | |
|---------------------|-----|
| Animal Models | 741 |
| Therapy | 742 |
| Prognosis | 745 |
| References | 745 |

IV DEGENERATIVE DISORDERS

67. Alzheimer Disease

DENNIS J. SELKOE

| | |
|---|-----|
| Introduction | 753 |
| Clinical Features and Diagnosis | 754 |
| Pathology | 755 |
| Biochemical Findings | 756 |
| Molecular Genetic Analysis of Alzheimer Disease | 758 |
| Therapy | 764 |
| References | 766 |

68. Genetics of Parkinson Disease and Related Diseases

JILL S. GOLDMAN AND STANLEY FAHN

| | |
|--------------------------------|-----|
| Introduction | 769 |
| Parkinson Disease | 769 |
| Parkinson-Plus Syndromes | 775 |
| Conclusions | 776 |
| References | 776 |
| Relevant Websites | 778 |

69. Frontotemporal Dementia

SHUNICHIRO SHINAGAWA AND BRUCE L. MILLER

| | |
|-------------------------------|-----|
| History and Terminology | 779 |
| Epidemiology | 779 |
| Clinical Syndromes | 780 |
| Diagnostic Criteria | 783 |
| Histopathology | 784 |
| Genetics | 785 |
| Treatment | 787 |
| Conclusions | 789 |
| References | 789 |

70. The Neuronal Ceroid-Lipofuscinoses (Batten Disease)

SARA E. MOLE AND MATTI HALTIA

| | |
|---|-----|
| Introduction | 793 |
| Historical Overview | 793 |
| Mode of Inheritance, Incidence and Prevalence | 796 |
| Natural History | 796 |
| Molecular Genetics | 798 |
| Disease Mechanisms | 799 |
| Differential Diagnosis and Testing | 800 |
| Management | 802 |
| Conclusion | 804 |
| Acknowledgements | 804 |
| References | 804 |
| Literature Cited in Tables | 806 |

V MOVEMENT DISORDERS

71. The Inherited Ataxias

ROGER N. ROSENBERG AND PRAVIN KHEMANI

| | |
|--|-----|
| Introduction..... | 811 |
| Autosomal Dominant Ataxias..... | 812 |
| Autosomal Recessive Ataxias..... | 823 |
| Other Recessive Ataxias..... | 826 |
| Mitochondrial Ataxias..... | 827 |
| Molecular Genetics..... | 827 |
| Therapeutic Strategies in Genetic Ataxias..... | 829 |
| References..... | 830 |

72. Friedreich Ataxia

MASSIMO PANDOLFO

| | |
|--|-----|
| Clinical Features..... | 833 |
| Pathology..... | 837 |
| Clinical and Molecular Genetics..... | 838 |
| Animal and Cellular Models..... | 840 |
| Pathogenesis of Friedreich Ataxia..... | 841 |
| Therapy..... | 841 |
| References..... | 842 |

73. Ataxia-Telangiectasia

SHUKI MIZUTANI

| | |
|---|-----|
| Clinical Features..... | 845 |
| Molecular Pathology..... | 845 |
| Diagnosis and Differential Diagnosis..... | 847 |
| Treatment and Prognosis..... | 848 |
| References..... | 848 |

74. Dystonia

KATJA LOHMANN AND CHRISTINE KLEIN

| | |
|---------------------------|-----|
| Definition..... | 849 |
| Classification..... | 849 |
| Genetic Causes..... | 849 |
| Pleiotropy..... | 857 |
| Susceptibility Genes..... | 858 |
| Acknowledgement..... | 858 |
| References..... | 858 |

75. Huntington Disease

ANDREW J. MCGARRY, KEVIN BIGLAN, AND FREDERICK MARSHALL

| | |
|-----------------------------|-----|
| Clinical Features..... | 861 |
| Molecular Genetics..... | 862 |
| Disease Mechanisms..... | 863 |
| Differential Diagnosis..... | 864 |
| Testing..... | 865 |
| Management..... | 865 |
| References..... | 866 |

76. Non-Parkinsonian Movement Disorders

STANLEY FAHN AND JILL S. GOLDMAN

| | |
|---|-----|
| Introduction..... | 869 |
| Essential Tremor..... | 869 |
| Dystonia..... | 869 |
| Chorea..... | 875 |
| Myoclonus Epilepsy..... | 881 |
| Paroxysmal Dyskinesias..... | 884 |
| Hereditary Hyperekplexia..... | 886 |
| Tourette Syndrome..... | 886 |
| Fragile X-Associated Tremor/Ataxia Syndrome..... | 887 |
| Movement Disorders, Genetics, Multidisciplinary Care, and the Future..... | 888 |
| References..... | 888 |
| Selected Reading..... | 890 |
| Relevant Websites..... | 890 |

77. Hereditary Spastic Paraplegia

JOHN K. FINK

| | |
|--|-----|
| Introduction..... | 891 |
| Genetic and Syndromic Classifications..... | 891 |
| Symptoms, Signs, and Course of Uncomplicated HSP..... | 891 |
| HSP Diagnosis..... | 898 |
| Complicated HSP..... | 899 |
| Clinical Variability and Genotype-Phenotype Correlation..... | 900 |
| Treatment..... | 900 |
| Prognosis..... | 900 |
| Neuropathology..... | 900 |
| Molecular Basis of HSP..... | 900 |
| Conclusions..... | 901 |
| Acknowledgements..... | 902 |
| References..... | 902 |

VI NEURO-ONCOLOGY

78. Glioblastoma

ELIZABETH A. MAHER AND ROBERT M. BACHOO

| | |
|-------------------------|-----|
| Introduction..... | 909 |
| Clinical Features..... | 910 |
| Molecular Genetics..... | 912 |
| Disease Mechanisms..... | 912 |
| Testing..... | 914 |
| Management..... | 914 |
| References..... | 916 |

VII NEURO CUTANEOUS DISORDERS

79. Neurofibromatoses

ADAM P. OSTENDORF AND DAVID H. GUTMANN

| | |
|-------------------------|-----|
| Introduction..... | 921 |
| Clinical Features..... | 921 |
| Molecular Genetics..... | 925 |

| | |
|------------------------------|-----|
| Disease Mechanism..... | 926 |
| Differential Diagnosis | 928 |
| Genetic Testing..... | 928 |
| Management | 928 |
| Future Directions | 929 |
| References | 929 |

80. Tuberous Sclerosis Complex

MONICA P. ISLAM AND E. STEVE ROACH

| | |
|-----------------------------------|-----|
| Introduction..... | 935 |
| Clinical Manifestations | 935 |
| Diagnostic Criteria..... | 940 |
| Genetic and Molecular Basis | 940 |
| References | 942 |

81. Sturge–Weber Syndrome

ANNE M. COMI, DOUGLAS A. MARCHUK, AND JONATHAN PEVSNER

| | |
|------------------------------|-----|
| Clinical Features | 945 |
| Natural History | 946 |
| Molecular Genetics..... | 946 |
| Disease Mechanisms | 948 |
| Differential Diagnosis | 949 |
| Testing..... | 950 |
| Management | 951 |
| Acknowledgements..... | 951 |
| References | 952 |

82. Hemangioblastomas of the Central Nervous System

ANA METELO AND OTHON ILIOPOULOS

| | |
|--------------------------|-----|
| Introduction..... | 955 |
| Clinical Features | 955 |
| Molecular Genetics..... | 957 |
| Disease Mechanisms | 957 |
| Diagnostic Testing | 958 |
| Management | 959 |
| References | 959 |

83. Incontinentia Pigmenti

A. YASMINE KIRKORIAN AND BERNARD COHEN

| | |
|--|-----|
| Introduction..... | 963 |
| Diagnostic Criteria for IP..... | 963 |
| Skin Manifestations of IP | 963 |
| CNS Manifestations of IP..... | 965 |
| Ocular Manifestations of IP..... | 966 |
| Disorders of Skin Appendages in IP | 966 |
| Bony Manifestations of IP | 966 |
| Dental and Oral Manifestations of IP | 966 |
| Other Minor Criteria..... | 967 |
| Genetics of IP | 967 |
| IP in Males | 967 |
| Treatment and Future Directions | 967 |
| References | 968 |

VIII EPILEPSY

84. The Genetic Epilepsies

ROBERT L. MACDONALD AND MARTIN J. GALLAGHER

| | |
|---|-----|
| Introduction..... | 973 |
| Defining Epilepsy Genes and Genetic Epilepsy Syndromes..... | 975 |
| Human Genetic Epilepsy Syndromes | 977 |
| Pathophysiology of Selected Epilepsy Gene Mutations | 986 |
| Conclusion..... | 993 |
| References..... | 994 |

IX WHITE MATTER DISEASES

85. Multiple Sclerosis

STEPHEN L. HAUSER, JORGE R. OKSENBERG, AND SERGIO E. BARANZINI

| | |
|----------------------------------|------|
| Introduction..... | 1001 |
| Clinical Features | 1001 |
| Diagnosis | 1002 |
| Disease-Modifying Treatment..... | 1004 |
| Pathology | 1005 |
| Immunologic Basis..... | 1006 |
| Epidemiology..... | 1008 |
| Genetic Basis of MS..... | 1009 |
| Conclusions..... | 1012 |
| References..... | 1012 |

86. Vanishing White Matter Disease

ORNA ELROY-STEIN AND RAPHAEL SCHIFFMANN

| | |
|---|------|
| Clinical Features | 1015 |
| Molecular Genetics..... | 1016 |
| Disease Mechanisms and Pathophysiology..... | 1021 |
| Differential Diagnosis | 1025 |
| Testing..... | 1026 |
| Management | 1027 |
| References..... | 1027 |

X NEUROPATHIES AND NEURONOPATHIES

87. Amyotrophic Lateral Sclerosis

JEMEEN SREEDHARAN AND ROBERT H. BROWN, JR.

| | |
|--|------|
| Introduction..... | 1033 |
| Altered Conformational Stability and Turnover of Critical Proteins in ALS..... | 1035 |
| Defects in Rna Processing Genes and Proteins in ALS | 1040 |
| Candidate Als Genes Implicated in Transcriptional Regulation..... | 1044 |
| Perturbations in Aspects of Axonal Biology in ALS | 1044 |
| Genome-Wide Association Studies (GWAS) in ALS..... | 1045 |
| References..... | 1046 |

88. Peripheral Neuropathies

STEVEN S. SCHERER, KLEOPAS A. KLEOPA, AND MERRILL D. BENSON

| | |
|---|------|
| Introduction..... | 1051 |
| Classifying Inherited Neuropathies..... | 1051 |
| Diagnosis and Treatment of CMT and Related Disorders..... | 1069 |
| Amyloid Neuropathies..... | 1070 |
| Acknowledgements..... | 1073 |
| References..... | 1073 |

89. Spinal Muscular Atrophy

BAKRI H. ELSHEIKH, W. DAVID ARNOLD, AND JOHN T. KISSEL

| | |
|-----------------------------|------|
| Clinical Features..... | 1075 |
| Molecular Genetics..... | 1079 |
| Disease Mechanisms..... | 1080 |
| Differential Diagnosis..... | 1081 |
| Testing..... | 1082 |
| Management..... | 1082 |
| References..... | 1084 |

90. Pain Genetics

WILLIAM RENTHAL

| | |
|----------------------------------|------|
| Introduction..... | 1089 |
| Neurobiology of Pain..... | 1089 |
| Mendelian Disorders of Pain..... | 1092 |
| Non-Mendelian Pain Genetics..... | 1098 |
| Future Directions..... | 1099 |
| Concluding Remarks..... | 1100 |
| References..... | 1100 |

XI MUSCLE AND NEUROMUSCULAR JUNCTION DISORDERS

91. Dystrophinopathies

ERIC P. HOFFMAN

| | |
|--|------|
| Historical Overview..... | 1103 |
| Mode of Inheritance and Prevalence..... | 1104 |
| Natural History..... | 1104 |
| Disease Variants..... | 1105 |
| End of Life: Mechanisms and Comorbidities..... | 1106 |
| Molecular Genetics..... | 1106 |
| Biochemistry..... | 1108 |
| Pathophysiology and Animal Models..... | 1108 |
| Experimental Therapy and Future Research Directions..... | 1109 |
| References..... | 1110 |

92. Limb-Girdle Muscular Dystrophy

WEN-CHEN LIANG AND ICHIZO NISHINO

| | |
|-------------------|------|
| Introduction..... | 1113 |
| LGMD1..... | 1113 |
| LGMD2..... | 1115 |

| | |
|--|------|
| Animal Models | 1117 |
| Differential Diagnosis | 1117 |
| Management and Future Perspectives | 1118 |
| References | 1118 |

93. The Congenital Myopathies

HEINZ JUNGBLUTH, CAROLINE SEWRY, AND FRANCESCO MUNTONI

| | |
|---|------|
| Introduction | 1121 |
| Clinical and Histopathological Features | 1121 |
| Molecular Genetics and Disease Mechanisms | 1126 |
| Differential Diagnosis | 1127 |
| Testing | 1127 |
| Management | 1128 |
| References | 1128 |

94. The Distal Myopathies

AMI MANKODI, BJARNE UDD, AND ROBERT C. GRIGGS

| | |
|--|------|
| Introduction | 1131 |
| Late Adult-Onset Distal Myopathies | 1131 |
| Early Adult-Onset Distal Myopathies | 1137 |
| Early-Onset Distal Myopathies | 1139 |
| Single Distal Myopathy Families with Unknown Molecular Cause | 1141 |
| Conclusion | 1141 |
| References | 1141 |

95. Hereditary Inclusion-Body Myopathies

ALDOBRANDO BROCCOLINI AND MASSIMILIANO MIRABELLA

| | |
|--|------|
| Introduction | 1145 |
| GNE Myopathy | 1145 |
| Hereditary Inclusion-Body Myopathy with Paget Disease of the Bone and Frontotemporal Dementia | 1149 |
| Hereditary Inclusion-Body Myopathy with Congenital Joint Contractures and External Ophthalmoplegia | 1150 |
| Other Variants of Hereditary Inclusion-Body Myopathy | 1151 |
| References | 1151 |

96. The Myotonic Dystrophies

RICHARD T. MOXLEY, III, JAMES E. HILBERT, AND GIOVANNI MEOLA

| | |
|--|------|
| Introduction | 1153 |
| Clinical Features | 1154 |
| Natural History | 1154 |
| Molecular Genetics | 1158 |
| Differential Diagnosis and Testing | 1161 |
| Management | 1162 |
| References | 1164 |

97. Facioscapulohumeral Dystrophy

RABI TAWIL

| | |
|------------------------------|------|
| Clinical Features | 1169 |
| Molecular Genetics | 1171 |
| Disease Mechanisms | 1172 |
| Differential Diagnosis | 1172 |
| Testing | 1173 |
| Management | 1174 |
| References | 1174 |

98. Muscle Channelopathies: Periodic Paralysis and Nondystrophic Myotonias

JEFFREY RALPH AND LOUIS PTÁČEK

| | |
|--|------|
| Introduction..... | 1177 |
| Clinical Features..... | 1177 |
| Molecular Genetics and Disease Mechanisms..... | 1181 |
| Differential Diagnosis..... | 1185 |
| Testing..... | 1186 |
| Management..... | 1187 |
| Acknowledgement..... | 1188 |
| References..... | 1188 |

99. Congenital Myasthenic Syndromes

ANDREW G. ENGEL

| | |
|---|------|
| Introduction..... | 1191 |
| Presynaptic CMS..... | 1193 |
| Defects in Basal Lamina Proteins..... | 1194 |
| Defects in AChR..... | 1196 |
| Defects in Mechanisms Governing EP Development and Maintenance..... | 1201 |
| Defects of Glycosylation..... | 1203 |
| Other Myasthenic Syndromes..... | 1204 |
| Pharmacotherapy of the CMS..... | 1205 |
| References..... | 1206 |

XII STROKE

100. Cerebral Vasculopathies

MICHAEL M. DOWLING

| | |
|---|------|
| Introduction..... | 1211 |
| Inborn Errors of Metabolism with Cerebrovascular Involvement..... | 1211 |
| Genetic Disorders with Early Atherosclerosis..... | 1214 |
| Genetic Disorders with Increased Prevalence of Dissection..... | 1214 |
| Moyamoya..... | 1216 |
| Genetic Causes of Small Vessel Disease..... | 1218 |
| References..... | 1219 |

101. Coagulopathies

FENELLA J. KIRKHAM

| | |
|---|------|
| Introduction..... | 1223 |
| β -Fibrinogen on Chromosome 4q28..... | 1223 |
| Factor II (Prothrombin) Gene 20210g > a on 11p11-Q12..... | 1225 |
| Factor V Leiden..... | 1226 |
| Thermolabile Methylene Tetrahydrofolate Reductase Polymorphism..... | 1228 |
| Disease Mechanisms..... | 1229 |
| Management..... | 1230 |
| Summary and Future Directions..... | 1231 |
| References..... | 1231 |

102. Sickle Cell Disease

FENELLA J. KIRKHAM

| | |
|------------------------------|------|
| Introduction..... | 1237 |
| Disease Characteristics..... | 1237 |

| | |
|---|------|
| Clinical Features | 1238 |
| Natural History | 1238 |
| Molecular Genetics..... | 1239 |
| Pathology | 1239 |
| Clinical Presentation | 1239 |
| Disease Mechanisms and Pathophysiology..... | 1242 |
| Testing..... | 1243 |
| Management | 1244 |
| Discussion | 1246 |
| Acknowledgements..... | 1246 |
| References | 1246 |

XIII PSYCHIATRIC DISEASE

103. Depression

STEVEN T. SZABO AND CHARLES B. NEMEROFF

| | |
|--|------|
| Introduction..... | 1253 |
| Clinical Features | 1253 |
| Pathology: Biochemical Alterations..... | 1257 |
| Pathology: Functional Neurobiology..... | 1264 |
| Pathology: Neural Plasticity and Resilience..... | 1264 |
| Treatment: Mechanism of Antidepressant Action | 1265 |
| Genetics: Unipolar Depression as a Heritable Disease | 1268 |
| Genetic Studies: The Search for Quantitative Traits | 1268 |
| Epigenetics: Environmental Influence At the Genetic Level..... | 1269 |
| Conclusion: Reducing Burden by Increasing Therapeutic Effect | 1270 |
| Financial Disclosures | 1270 |
| References | 1270 |

104. Bipolar Disorder

SCOTT C. FEARS AND VICTOR I. REUS

| | |
|----------------------------|------|
| Introduction..... | 1275 |
| Clinical Features | 1275 |
| Genetic Epidemiology | 1277 |
| Disease Mechanisms | 1280 |
| Molecular Genetics..... | 1284 |
| Animal Models | 1287 |
| Management | 1287 |
| Conclusion..... | 1288 |
| References | 1288 |

105. Schizophrenia

DAVID W. VOLK AND DAVID A. LEWIS

| | |
|------------------------------|------|
| Introduction..... | 1293 |
| Clinical Features | 1293 |
| Molecular Genetics..... | 1294 |
| Disease Mechanisms | 1295 |
| Differential Diagnosis | 1296 |
| Testing..... | 1296 |
| Management | 1297 |
| References | 1297 |

106. Obsessive–Compulsive Disorder

MICHAEL H. BLOCH, JESSICA B. LENNINGTON, GABOR SZUHAY, AND PAUL J. LOMBROSO

| | |
|---|------|
| Introduction..... | 1301 |
| Clinical Features..... | 1301 |
| Molecular Genetics..... | 1303 |
| Disease Mechanisms: Pathophysiology and Current Research..... | 1303 |
| Differential Diagnosis..... | 1304 |
| Testing..... | 1305 |
| Management..... | 1305 |
| Conclusion..... | 1307 |
| References..... | 1308 |

107. Tourette Syndrome

JESSICA B. LENNINGTON, MICHAEL H. BLOCH, LAWRENCE D. SCAHILL, GABOR SZUHAY, PAUL J. LOMBROSO,
AND FLORA M. VACCARINO

| | |
|---|------|
| Summary..... | 1311 |
| Clinical Features..... | 1311 |
| Disease Mechanisms: Pathophysiology and Current Research..... | 1313 |
| Differential Diagnosis..... | 1315 |
| Testing..... | 1315 |
| Management..... | 1315 |
| Conclusions..... | 1317 |
| Acknowledgements..... | 1317 |
| References..... | 1317 |

108. Addiction

SCOTT D. PHILIBIN AND JOHN C. CRABBE

| | |
|---|------|
| Disease Characteristics, Clinical Features and Diagnostic Evaluation..... | 1321 |
| Human Molecular and Genetic Data..... | 1321 |
| Behavioral Neuroscience Frameworks..... | 1323 |
| Genetic Animal Models..... | 1324 |
| Molecular Approaches..... | 1325 |
| Therapy..... | 1326 |
| Conclusions and Future Directions..... | 1327 |
| Acknowledgements..... | 1328 |
| References..... | 1328 |

XIV A NEUROLOGIC GENE MAP

109. A Neurologic Gene Map

SAIMA N. KAYANI, KATHLEEN S. WILSON, AND ROGER N. ROSENBERG

| | |
|-----------------|------|
| References..... | 1400 |
|-----------------|------|

| | |
|------------|------|
| Index..... | 1401 |
|------------|------|

This page intentionally left blank

Preface to the Fifth Edition

We are publishing the fifth edition of the *Molecular and Genetic Basis of Neurological and Psychiatric Disease*. The first edition appeared in 1993 followed by editions in 1997, 2003, and 2008. We are most grateful for the foresight, dedication, and authorship of our former editors for the success of the first four editions. They are Stanley B. Prusiner, Salvatore DiMauro, Robert L. Barchi, Louis M. Kunkel, Henry L. Paulson, Louis Ptáček and Eric J. Nestler. The fifth edition is edited by Roger N. Rosenberg and Juan M. Pascual.

There are several major new aspects to the fifth edition: The text now includes well over 100 chapters and 200 contributors. Every chapter has been thoroughly updated either by previous contributors or by new experts in the field, all of which are of international renown. A standard, unified chapter format has been followed as much as possible. Most illustrations are new or have been newly drawn, and color has been used wherever helpful throughout the text. The book is available both in print and in up-to-date electronic format. Additional new chapters in this edition cover the following topics: DNA sequencing and other methods of exonic and genomic analysis; pharmacogenomics; causation and association; stem cells and therapeutic development; neuroimaging; genetic counseling; the ethics of cognitive enhancement and mental impairment; cerebral malformations; global developmental delay and intellectual disability; neurodegeneration with brain iron accumulation; pantothenate kinase deficiency; Wilson disease; Menkes disease and other ATP7A disorders; disorders of manganese transport; aceruloplasminemia; neurotransmitter disorders; frontotemporal dementias; dystonia; glioblastoma; tuberous sclerosis; von Hippel–Lindau disease; Sturge–Weber syndrome; incontinentia pigmenti; channelopathies; vanishing white matter disease; pyruvate metabolism and Krebs cycle disorders; pain; vasculopathies; coagulopathies; sickle cell disease; and autism. Clearly, neurogenetics/neurogenomics has advanced rapidly and is now poised to develop in the next decade effective targeted neurotherapeutics.

In the 21 years spanning the five editions of our book, molecular genomic analyses of the human genome have been implemented seeking the genetic basis for natural selection providing biological fitness and also risk of developing disease. Genome-wide association studies (GWAS) seeking gene variations, single nucleotide polymorphisms (SNP), causal of several human diseases have been conducted in recent years including autism, schizophrenia, obesity, diabetes and heart disease.

Several GWAS for risk association with neurological diseases, neuromic studies, have been reported. An increased risk for amyotrophic lateral sclerosis (ALS), Alzheimer disease (AD), restless leg syndrome (RLS), and multiple sclerosis have been associated with polymorphisms in specific genes. These observations have advanced an understanding of the causation of inherited, complex polygenetic, multifactorial neurological diseases. They have been made possible by the publication of the human genome and haplotype studies (HapMap analyses).

The hope with neurome-wide association studies has been that the complete complement of variant genes will be identified causal of the major neurodegenerative diseases. Then, pharmaconeuromic therapy would not be far behind. GWAS has provided new and important data of the major genes responsible for major human traits and common diseases. GWAS has provided insights into gene variations in low penetrant genes causal for polygenetic, multifactorial neurological disease, such as Alzheimer disease. Overall, about 400 genetic variants have been identified that contribute to human traits and diseases including neurological diseases.

Sequencing candidate genes for disease including their surrounding regions in thousands of people will be needed to discover more associations with disease. SNPs are turning out not to be a stringent enough level of analysis seeking genetic risks for disease. The change in mindset is going from seeking analyses of common, low-penetrance variants causal of common diseases to seeking rare low- or moderate-penetrance variants that have been missed by GWAS. It may be necessary to move beyond sequencing candidate genes and surrounding regions for disease association and begin sequencing whole genomes to find the missing heritability. Francis Collins, Director of the National Institutes of Health, has suggested that the 1000 genomes project, designed to sequence the genomes of at least 1000 people from all over the world, would provide a powerful approach to finding the hidden heritability.

The genetic explanations that would be of primary interest to find the missing heritability for genetic neurological disease missed by GWAS include copy-number variation (CNV), epistatic effects, and epigenetics. CNV refers to regions of DNA that are up to hundreds of base pairs long that are deleted or duplicated between individuals.

There are strong CNV associations between schizophrenics compared to normals and they may arise *de novo* in persons without a family history of the mutation. Epistasis, where one or more modifying genes reduce or enhance the effect of another gene, may be an important genetic mechanism at work to explain heritability not found by GWAS. Epigenetics is another vital area to be explored. It refers to changes in gene expression that are inherited but not caused by alteration in the sequence of the gene. We now know that gene expression is altered by methylation or acetylation, and also by inhibition of messenger RNA expression by iRNA or microRNA binding.

The 21,000 protein-coding genes in the human genome make up less than 1.2% of the human genome. Analysis of the remaining 98.8% of the human genome and its role in the causation of human neurological diseases, both inherited and acquired, is a formidable challenge yet unexplored to any degree. RNA transcripts and their effects on regulation and levels of gene expression is one of the next frontiers for neuromics.

Then there is the issue that natural selection only functions before or during the reproductive years and not afterwards, when Alzheimer disease and Parkinson disease occur. Natural selection has as its major biological function to select for fitness allowing for reproduction and maintenance of a lineage or species. Aging and neurodegenerative diseases seem to have escaped the forces of natural selection by occurring after the reproductive years. On the other hand, perhaps evolution has actually selected for aging and neurodegenerative diseases as a means to maintain the limits of a finite lifespan. Clearly, neuromics must address the molecular basis of brain aging and why the aging process provides a permissive environment to allow the opportunistic neuromic program causal of late-onset neurodegenerative diseases to be expressed.

The cause of Alzheimer disease is due both to genetic polymorphisms and environmental stimuli. In this view, environmental stimuli, to be determined, influence the production of an abnormal pattern of gene expression causal of Alzheimer disease. So, we will have to understand the process of natural selection in the context of the selection pressures from the environments that we inhabit. Darwin emphasized adaptation to a changing environment as the principal selective influence for evolution. This principle is valid studying the interaction of environmental stimuli and the genetic factors causal of neurodegenerative diseases.

Deriving induced pluripotent stem cells from late-onset Alzheimer disease patients and differentiating them into neuroblasts would be one way to screen compounds to see if an abnormal pattern of gene expression is produced compared to derived neuroblasts from normal controls. Here would be a method to link environment to the genetic program causal of Alzheimer disease. It would also be a means to screen potential therapeutic agents that correct an abnormal pattern of gene expression seen in AD patients as a prelude to a clinical trial.

The 200 years since Charles Darwin's birth, 150 years since the publication of *On the Origin of Species*, and the 20 years of the publication of the four editions of this book, is a brief time in human experience. The fifth edition builds on the development of neurogenetics during the past 20 years and documents the advances in genome sequencing, CNV, epistasis, epigenetics, RNA regulation of gene expression, and stem cell applications to decipher how mutations in these genetic functions are causal of neurological diseases.

We look forward to future editions of the book and wish to express our gratitude to our many loyal colleagues who have participated in all five editions, and thank our new authors for their contributions to maintain the book's scientific rigor and excellence. Whereas we have made every effort towards comprehensiveness and clarity, many omissions and imprecisions are bound to remain. To that effect, we will welcome comments and suggestions at Rosenberg5ed@gmail.com. We have retained the names of Hugo W. Moser and John H. Menkes through the kindness of their families to honor their memory. The outstanding editorial contributions of Kristi Anderson, project manager, Mica Haley, publisher for neuroscience, and Julia Haynes, book production project manager, are most gratefully acknowledged. We are also thankful to our families, patients, colleagues and trainees both for interactions and for lost time while we were working on the fifth edition. While a textbook on the human experience of neurological or psychiatric patients has not yet been written, we hope that ours will assist in the understanding of one important dimension of their existence.

Roger N. Rosenberg
Juan M. Pascual
Editors

Contributors

- Nicholas Ah Mew** The Center for Neuroscience and Behavioral Medicine, Department of Genetics and Metabolism, Children's National Medical Center, Washington, DC, USA
- Wado Akamatsu** Department of Physiology, School of Medicine, Keio University, Tokyo, Japan
- Hasan Orhan Akman** Department of Neurology, Columbia University Medical Center, New York, NY, USA
- Koji Aoyama** Department of Pharmacology, Teikyo University School of Medicine, Tokyo, Japan
- W. David Arnold** Department of Neurology, The Ohio State University, Wexner Medical Center, Columbus, OH, USA
- Rafael Artuch** Hospital Sant Joan de Déu, Barcelona, Spain; CIBERER (Network for Research in Rare Diseases), Instituto de Salud Carlos III, Madrid, Spain
- Robert M. Bachoo** Departments of Internal Medicine and Neurology & Neurotherapeutics, Annette G. Strauss Center for Neuro-Oncology, Simmons Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Sergio E. Baranzini** Department of Neurology, University of California, San Francisco, CA, USA
- Michael Beck** Children's Hospital, University Medical Center, University of Mainz, Mainz, Germany
- Merrill D. Benson** Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
- Vladimir M. Berginer** Department of Neurology, Soroka Medical Center, Beer Sheva, Israel
- Gerard T. Berry** Boston Children's Hospital, Division of Genetics and Genomics, Harvard Medical School, Boston, MA, USA
- Kevin M. Biglan** Department of Neurology, University of Rochester, Rochester, NY, USA
- Thomas D. Bird** Departments of Neurology and Medicine, University of Washington and VA Medical Center, Seattle, WA, USA
- D. Montgomery Bissell** National Institutes of Health (NIH)-supported Liver Center, Division of Gastroenterology, UCSF Medical Center, San Francisco, CA, USA
- Michael H. Bloch** Child Study Center, Yale University School of Medicine, New Haven, CT, USA
- Aldobrando Broccolini** Institute of Neurology, Department of Geriatrics, Neurosciences and Orthopedics, Catholic University, Rome, Italy
- Robert H. Brown, Jr.** Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA
- Allison Caban-Holt** Department of Behavioral Science, Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
- Brenda Canine** McLaughlin Research Institute, Great Falls, MT, USA
- C. Thomas Caskey** Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
- Patrick F. Chinnery** Department of Neurology, Institute of Genetic Medicine, Newcastle University, Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne, UK
- David T. Chuang** Departments of Biochemistry and Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Jacinta L. Chuang** Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Bernard A. Cohen** Dermatology and Pediatrics, Johns Hopkins Children's Center, Baltimore, MD, USA
- Anne M. Comi** Neurology and Pediatrics, Kennedy Krieger Institute, Johns Hopkins School of Medicine, Hunter Nelson Sturge-Weber Center, Baltimore, MD, USA
- Rody P. Cox** Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- John C. Crabbe** Department of Behavioral Neuroscience, Department of Veterans Affairs Medical Center Director, Portland Alcohol Research Center, Oregon Health & Science University, Portland, OR, USA
- Marie Y. Davis** Department of Neurology, University of Washington, Seattle, WA, USA
- Darryl C. De Vivo** SMA Clinical Research Center, Motor Neuron Center, Colleen Giblin Laboratories for Pediatric Neurology, Columbia University Medical Center, New York, NY, USA
- Robert J. Desnick** Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Stefano Di Donato** Fondazione IRCCS Istituto Neurologico "Carlo Besta," Milan, Italy
- Salvatore DiMauro** Department of Neurology, Columbia University Medical Center, The Neurological Institute of New York, New York, NY, USA
- Michael M. Dowling** Departments of Pediatrics, Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- David A. Dyment** Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada
- Florian S. Eichler** Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- Ramyiadarsini Elangovan** Functional Genomics Unit, Department of Physiology, Anatomy and Genetics and Medical Research Council, University of Oxford, Oxford, UK

- Bernice Elger** Institute of Biomedical Ethics, University of Basel, Basel, Switzerland
- Sara Elrefai** Department of Medical Genetics, Henry Ford Hospital, Detroit, MI, USA
- Orna Elroy-Stein** Department of Cell Research and Immunology, Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
- Bakri H. Elsheikh** Saudi Aramco, Dhahran, Saudi Arabia
- Andrew G. Engel** Mayo Clinic College of Medicine, Department of Neurology, Mayo Clinic, Rochester, MN, USA
- Patricia Evans** Department of Neurology and Pediatrics, The University of Texas Southwestern School of Medicine, Dallas, TX, USA
- Stanley Fahn** Movement Disorder Division, Department of Neurology, Neurological Institute, Columbia University Medical Center, New York, NY, USA
- Scott C. Fears** Ronald Reagan UCLA Medical Center, Stewart and Lynda Resnick Neuropsychiatric Hospital at UCLA, Los Angeles, CA, USA
- John K. Fink** Department of Neurology, University of Michigan, Geriatric Research Education and Care Center, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, MI, USA
- Theodore Friedmann** Department of Pediatrics, UCSD School of Medicine, La Jolla, CA, USA
- Martin J. Gallagher** Department of Neurology, Vanderbilt University, Nashville, TN, USA
- Àngels García-Cazorla** Department of Neurology, Hospital Sant Joan de Déu, Barcelona, Spain; CIBERER (Network for Research in Rare Diseases); Instituto de Salud Carlos III, Madrid, Spain
- Jill S. Goldman** Taub Institute, Columbia University Medical Center, New York, NY, USA
- Sailaja Golla** Neurodevelopmental Pediatrics, Division of Pediatric Neurology, The University of Texas Southwestern Medical Center, Children's Medical Center, Dallas TX, USA
- Sidney M. Gospe, Jr.** Departments of Neurology and Pediatrics, University of Washington, and Seattle Children's Hospital, Seattle, WA, USA
- William D. Graf** Department of Pediatrics, Department of Neurology, Yale School of Medicine, New Haven, CT, USA
- Robert C. Griggs** Departments of Neurology, Pathology and Laboratory Medicine and Pediatrics, University of Rochester Medical Center, Rochester, NY, USA
- Andrea L. Gropman** Division of Neurogenetics and Developmental Pediatrics, Department of Neurology and Pediatrics, Children's National Medical Center and the George Washington University of the Health Sciences, Washington, DC, USA
- Yian Gu** Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Medical Center, New York, NY, USA
- Teresa M. Gunn** McLaughlin Research Institute, Great Falls, MT, USA
- David H. Gutmann** Department of Neurology, Washington University Neurofibromatosis Center, Washington University School of Medicine, St. Louis, MO, USA
- Richard Haas** Departments of Neurosciences and Pediatrics, University of California, San Diego, La Jolla, CA, USA
- Randi J. Hagerman** MIND Institute, UC Davis Health System, Sacramento, CA, USA
- Matti J. Haltia** Department of Pathology, Children's Hospital, University of Helsinki, Helsinki, Finland
- Emma B. Hare** MIND Institute, UC Davis Medical Center, Sacramento, CA, USA
- Tamar Harel** Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
- Stephen L. Hauser** Department of Neurology, University of California, San Francisco, CA, USA
- Elizabeth Head** Department of Molecular and Biomedical Pharmacology, Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
- James E. Hilbert** Department of Neurology, Neuromuscular Disease Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
- Eric P. Hoffman** Research Center for Genetic Medicine, Children's Research Institute, Department of Integrative Systems Biology, George Washington University, Washington, DC, USA
- Othon Iliopoulos** Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA
- Hiroyuki Ishiura** Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- Monica P. Islam** Department of Clinical Pediatrics, The Ohio State University College of Medicine, Department of Pediatric Neurology, Nationwide Children's Hospital, Columbus, OH, USA
- Clifford R. Jack, Jr.** Aging and Dementia Imaging Laboratory, Department of Radiology, Mayo Clinic, Rochester, MN, USA
- William G. Johnson** Laboratory of Molecular Neurogenetics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
- Fabrice Jotterand** Department of Health Care Ethics, Regis University, Denver, CO, USA; Institute of Biomedical Ethics, University of Basel, Basel, Switzerland
- Heinz Jungbluth** Department of Clinical Neuroscience, King's College London, Guy's & St. Thomas' Hospital NHS Foundation Trust, London, UK
- John P. Kane** Departments of Medicine, Biochemistry and Biophysics, Cardiovascular Research Institute, UCSF Medical Center, San Francisco, CA, USA
- Clara van Karnebeek** Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada
- Saima N. Kayani** Department of Neurology and Neurotherapeutics, and Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Pravin Khemani** Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Fenella J. Kirkham** Department of Paediatric Neurology, Neurosciences Unit, Institute of Child Health, University College London, London, UK

- A. Yasmine Kirkorian** Division of Pediatric Dermatology, Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- John T. Kissel** Department of Neurology and Pediatrics, Wexner Medical Center, The Ohio State University, Columbus, OH, USA
- Christine Klein** Institute of Neurogenetics and, Department of Neurology, University of Lübeck, Lübeck, Germany
- Kleopas A. Kleopa** Department of Clinical Neurosciences, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
- Satoshi Kono** First Department of Medicine, Hamamatsu University School of Medicine, Handayama, Hamamatsu, Japan
- Michael C. Kruer** University of South Dakota Sanford School of Medicine, Sanford Children's Specialty Clinic, Sanford Children's Research Center, Sioux Falls, SD, USA
- Walter A. Kukull** Department of Epidemiology, University of Washington, Seattle, WA, USA
- Jessica B. Lennington** Child Study Center, Yale University School of Medicine, New Haven, CT, USA
- David A. Lewis** Department of Psychiatry, University of Pittsburgh, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA
- Wen-Chen Liang** Department of Pediatrics, Kaohsiung Medical University Hospital, Department of Pediatrics, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- Katja Lohmann** Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
- Paul J. Lombroso** Child Study Center, Yale University School of Medicine, New Haven, CT, USA
- Reymundo Lozano** MIND Institute, UC Davis Medical Center, Sacramento, CA, USA
- James R. Lupski** Department of Pediatrics, Department of Molecular and Human Genetics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA
- Paola Luzi** Department of Neurology, Assistant Director, Lysosomal Diseases Testing Laboratory, Jefferson Medical College, Philadelphia, PA, USA
- Qian Ma** Rare Brain Disorders Program, Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Robert L. Macdonald** Department of Neurology, Vanderbilt University, Nashville, TN, USA
- Gustavo H.B. Maegawa** McKusick-Nathans Institute of Genetic Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Elizabeth A. Maher** Departments of Internal Medicine and Neurology & Neurotherapeutics, Annette G. Strauss Center for Neuro-Oncology, Simmons Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Mary J. Malloy*** Departments of Medicine and Pediatrics, Cardiovascular Research Institute, UCSF Medical Center, San Francisco, CA, USA
- Ami K. Mankodi** Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
- Douglas A. Marchek** Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA
- Isaac Marin-Valencia** Rare Brain Disorders Program, Department of Neurology and Neurotherapeutics, Department of Pediatrics, Division of Pediatric Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Frederick J. Marshall** Geriatric Neurology Unit, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
- James A. Mastrianni** Center for Comprehensive Care and Research on Memory Disorders, Department of Neurology, The University of Chicago, Chicago, IL, USA
- Reuben Matalon** Department of Pediatrics, The University of Texas Medical Branch (UTMB), Galveston, TX, USA
- Richard Mayeux** Gertrude H. Sergievsky Center, Taub Institute on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY, USA
- Jennifer L. McCurdy** Department of Health Care Ethics, Rueckert-Hartman College of Health Professions, Regis University, Denver, CO, USA
- Andrew J. McGarry** Department of Neurology, Cooper University Health Care, Cherry Hill, NJ, USA
- John H. Menkes*** Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Giovanni Meola** Department of Neurology, University of Milan, IRCCS Policlinico San Donato, Milan, Italy
- Ana Metelo** Faculty of Science and Technology, Coimbra University, Coimbra; Portugal; Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA
- Kimberlee Michals Matalon** Health and Human Performance, The University of Houston, Houston, TX, USA
- Bruce L. Miller** Neurology, Memory and Aging Center, University of California, San Francisco, CA, USA
- Massimiliano Mirabella** Institute of Neurology, Department of Geriatrics, Neurosciences and Orthopedics, Catholic University, Rome, Italy
- Justin Miron** Department of Neuroscience, McGill University, Montreal, QC, Canada
- Jun Mitsui** Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- Hiroaki Miyajima** First Department of Medicine, Hamamatsu University School of Medicine, Handayama, Hamamatsu, Japan
- Shuki Mizutani** Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Graduate School of Medicine, Yushima, Tokyo, Japan
- Sara E. Mole** MRC Laboratory for Molecular Cell Biology, UCL Institute of Child Health, University College London, London, UK
- Lisa M. Monteggia** Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, TX, USA

*Deceased

- Hugo W. Moser** Department of Neurogenetics, Johns Hopkins University, Kennedy Krieger Institute, Baltimore, MD, USA
- Mary Ann Morris** Department of Neurology and Neurotherapeutics, The University of Texas Southwestern School of Medicine, Dallas, TX, USA
- Richard T. Moxley, III** Department of Neurology and Pediatrics, Neuromuscular Disease Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
- Jennifer M. Mueller** Division of Genetics and Metabolism, Department of Pediatrics, University of Florida, Gainesville, FL, USA
- Francesco Muntoni** Department of Paediatric Neurology, Dubowitz Neuromuscular Centre, UCL Institute of Child Health, London, UK
- Melissa E. Murray** Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
- Toshio Nakaki** Department of Pharmacology, Teikyo University School of Medicine, Tokyo, Japan
- Charles B. Nemeroff** Department of Psychiatry and Behavioral Sciences, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA
- Ichizo Nishino** Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan
- William L. Nyhan** Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
- Hideyuki Okano** Department of Physiology, School of Medicine, Keio University, Tokyo, Japan
- Jorge R. Oksenberg** Department of Neurology, University of California, San Francisco, CA, USA
- Adam P. Ostendorf** Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
- Massimo Pandolfo** Université Libre de Bruxelles, ULB Institute of Neurosciences (UNI), Department of Neurology, Hôpital Erasme, Brussels, Belgium
- Maria Belen Pappa** Division of Neurogenetics and Developmental Pediatrics, Department of Neurology and Pediatrics, Children's National Medical Center and the George Washington University of the Health Sciences, Washington, DC, USA
- Carmen Paradás** Unidad de Enfermedades Neuromusculares, Servicio de Neurología, Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Seville, Spain
- Juan M. Pascual** Rare Brain Disorders Program, Departments of Neurology and Neurotherapeutics, Physiology and Pediatrics and Eugene McDermott Center for Human Growth & Development/ Center for Human Genetics. Division of Pediatric Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Gregory M. Pastores** Adult Metabolic Service, Department of Medicine, National Centre for Inherited Metabolic Disorders Mater Misericordiae University Hospital, Dublin, Ireland
- Shailendra B. Patel** Division of Endocrinology, Metabolism and Clinical Nutrition, Clement J Zablocki Veterans Medical Center, Medical College of Wisconsin, Milwaukee, WI, USA
- Marc C. Patterson** Division of Child and Adolescent Neurology, Departments of Neurology, Pediatrics and Medical Genetics, Mayo Clinic Children's Center, Rochester, MN, USA
- Davut Pehlivan** Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
- Scott D. Philibin** Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Cynthia Picard** Department of Neuroscience, McGill University, Montreal, QC, Canada
- Judes Poirier** Centre for Studies on the Prevention of Alzheimer's Disease, Douglas Mental Health University Institute, Montreal, QC, Canada
- Louis J. Ptáček** Department of Neurology, Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA, USA
- Geetha L. Radhakrishnan** Department of Pediatrics, The University of Texas Medical Branch (UTMB), Galveston, TX, USA
- Jeffrey W. Ralph** Department of Neurology, University of California, San Francisco, CA, USA
- Sreeram V. Ramagopalan** Functional Genomics Unit, Department of Physiology, Anatomy and Genetics and Medical Research Council, University of Oxford, Oxford, UK
- Gerald V. Raymond** Department of Neurology, University of Minnesota, Minneapolis, MN, USA
- William Renthall** Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Victor I. Reus** Department of Psychiatry, University of California San Francisco School of Medicine, San Francisco, CA, USA
- E. Steve Roach** Department of Pediatrics and Neurology, The Ohio State University College of Medicine, Nationwide Children's Hospital, Columbus, OH, USA
- Roger N. Rosenberg** Department of Neurology and Neurotherapeutics, Department of Physiology, Section of Cognitive and Memory Disorders, Alzheimer's Disease Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- David S. Rosenblatt** Departments of Human Genetics, Medicine, Pediatrics and Biology, McGill University, Montreal, QC, Canada
- Gerald Salen** Division of Gastroenterology, Rutgers, New Jersey Medical School, Newark, NJ, USA
- Konrad Sandhoff** LIMES, Kekulé-Institut, Bonn University, Bonn, Germany
- Lawrence D. Scahill** Department of Pediatrics, Marcus Autism Center, Emory University School of Medicine, Atlanta, GA, USA
- Steven S. Scherer** Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

- Raphael Schiffmann** Institute of Metabolic Disease, Baylor Research Institute, Dallas, TX, USA
- Detlev Schindler** Department of Human Genetics, University of Würzburg, Würzburg, Germany
- Frederick Schmitt** Department of Neurology, Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
- Susanne A. Schneider** Department of Neurology, University of Kiel, Kiel, Germany
- Eric A. Schon** Department of Neurology, Columbia University Medical Center, The Neurological Institute of New York, New York, NY, USA
- Edward H. Schuchman** Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Nicole Schupf** The Gertrude H. Sergievsky Center, Columbia University Medical Center, New York, NY, USA
- Margretta Reed Seashore** Departments of Genetics, Laboratory Medicine and Pediatrics, Yale University School of Medicine, New Haven, CT, USA
- Dennis J. Selkoe** Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA
- Caroline Sewry** Dubowitz Neuromuscular Centre, UCL Institute of Child Health and Great Ormond Street Hospital for Children, London, UK; RJA Orthopaedic Hospital, Oswestry, UK
- Michael Shevell** Departments of Pediatrics and Neurology/Neurosurgery, McGill University, Montreal Children's Hospital/McGill University Health Centre, Montreal, QC, Canada
- Shunichiro Shinagawa** Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan
- Jemeen Sreedharan** Babraham Institute, Cambridge, UK
- Myriam Srour** Departments of Pediatrics and Neurology/Neurosurgery, McGill University, Division of Pediatric Neurology, Montreal Children's Hospital/McGill University Health Centre, Montreal, QC, Canada
- Kazuma Sugie** Department of Neurology, Nara Medical University School of Medicine, Nara, Japan, Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan
- Kristen L. Szabla** Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Steven T. Szabo** Department of Psychiatry and Behavioral Sciences, Division of Translational Psychiatry, Duke University Medical Center, Durham, NC, USA
- Gábor Szuhay** Child Study Center, Yale University School of Medicine, New Haven, CT, USA
- Franco Taroni** Fondazione IRCCS Istituto Neurologico "Carlo Besta," Milan, Italy
- Rabi Tawil** Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
- Mireia Tondo** Rare Brain Disorders Program, Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Shoji Tsuji** Department of Neurology, Neuroscience Program, Graduate School of Medicine, Medical Genome Center, The University of Tokyo Hospital, The University of Tokyo, Tokyo, Japan
- Bjarne Udd** Department of Neurology, Neuromuscular Research Center, University and University Hospital of Tampere, Tampere, Finland, Folkhalsan Institute of Genetics, University of Helsinki, Helsinki, Finland; Vasa Central Hospital, Department of Neurology, Vasa, Finland
- Wendy R. Uhlmann** Departments of Internal Medicine and Human Genetics, University of Michigan Medical School, Ann Arbor, MI, USA
- Flora M. Vaccarino** Child Study Center, Program in Neurodevelopment and Regeneration, Yale Kavli Institute for Neuroscience, Yale University School of Medicine, New Haven, CT, USA
- Prashanthi Vemuri** Aging and Dementia Imaging Laboratory, Department of Radiology, Mayo Clinic, Rochester, MN, USA
- Charles P. Venditti** Organic Acid Research Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
- David W. Volk** Department of Psychiatry, University of Pittsburgh, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA
- Dong Wang** Department of Neurology, Southern Regional Medical Center, Riverdale, GA, USA
- David Watkins** Department of Human Genetics, McGill University, Montreal, QC, Canada
- David A. Wenger** Department of Neurology, Director, Lysosomal Diseases Testing Laboratory, Jefferson Medical College, Philadelphia, PA, USA
- Charles A. Williams** Division of Genetics and Metabolism, Department of Pediatrics, University of Florida, Gainesville, FL, USA
- Kathleen S. Wilson** Department of Pathology and the McDermott Center for Human Growth and Development, Cytogenomic Microarray Analysis Laboratory, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Golder N. Wilson** Department of Pediatrics, Texas Tech University Health Science Centers, Amarillo and Lubbock (Pediatrics), KinderGenome Genetic Practice, Medical City Hospital, Dallas, TX, USA
- Barry Wolf** Department of Medical Genetics, Henry Ford Hospital, Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA
- R. Max Wynn** Departments of Biochemistry and Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA
- Shihui Yu** Department of Pathology and Laboratory Medicine, Seattle Children's Hospital and University of Washington School of Medicine, Seattle, WA, USA

This page intentionally left blank

S E C T I O N I

GENERAL CONCEPTS AND TOOLS

This page intentionally left blank

Mendelian, Non-Mendelian, Multigenic Inheritance, and Epigenetics

*Tamar Harel**, *Davut Pehlivan**, *C. Thomas Caskey**, and *James R. Lupski*[†]*

*Baylor College of Medicine, Houston, TX, USA

[†]Texas Children's Hospital, Houston, TX, USA

INTRODUCTION

Genetic influence on neurologic disease expression can include the contribution of a highly penetrant Mendelian variant (HPMV) and be the most prominent and perhaps singular factor required to manifest a disease phenotype, or it can be a genetic modifier and one relatively minor component of many different disease-associated factors. Perhaps the best example of the former is monogenic Mendelian disorders with complete penetrance wherein a mutation in a single disease-causing gene usually results in a relatively uniform disease phenotype. The latter pattern can be observed in many common diseases in which genetic factors contribute a portion of the risk and may play a role in either increasing or decreasing disease susceptibility. Between these extremes of genetic pathophysiology, however, there is a continuum of genetic influence on disease pathophysiology.

Mendelian traits represent the most basic and simple pattern of inheritance. Mutations in a gene encoded on an autosome or sex chromosome result in specific inheritance patterns. Non-Mendelian traits reveal some complexity in their mode of inheritance, in which the classic pattern of inheritance may not always apply, and epigenetic factors are often associated with disease mechanisms. Furthermore, in some diseases one gene is not sufficient to cause the clinical phenotype, but when two or more genes are involved, a particular disease becomes apparent. This latter mechanism is usually referred to as multigenic inheritance, and termed oligogenic inheritance when only a small number of genes are involved and digenic inheritance when variation or mutation in two genes is a prerequisite to disease trait manifestation. Finally, complex traits can involve multiple genes as susceptibility or protective factors but also require internal factors, including other health conditions, as well as external factors such as environment, lifestyle, diet, accident, infection, and drug exposure.

Regardless of the mode of inheritance, defining specific genetic factors that are associated with certain diseases and their functional role in phenotypic manifestations is important for patient management and genetic counseling, as well as for understanding disease mechanisms at the molecular level and ultimately developing new therapeutic approaches. Molecular diagnostics contribute to patient management by establishing an accurate diagnosis, by enabling presymptomatic or prenatal diagnosis, by providing prognostic information, and by further refining or subclassifying more general diagnostic labels. It is estimated that approximately one-third of all human genes are expressed in the nervous system; thus, neurogenetic phenotypes are common.¹ This chapter provides an update to the corresponding chapter by Shiga et al.² in the previous edition of this book; here we review the modes of inheritance that can be observed in various human neurologic and psychiatric diseases, and how genetics and more recently genomics is increasing our molecular understanding of neurological disease.

MENDELIAN TRAITS

Mendel's Laws

The basic rules of inheritance were delineated from first principles by Gregor Mendel based upon his observation of the segregation of traits in the common garden pea, *Pisum sativum*.³ Mendel's first law, the principle of independent segregation, referred to the ability of genes, which he called factors, to segregate independently during the formation of gametes or sex cells. Mendel's second law, the principle of independent assortment, was derived from his observations using peas that differed by more than one characteristic or trait. Mendel postulated that only one factor from each pair was independently transmitted to the gamete during sex-cell formation and that any one gamete contains only one type of inherited factor from each pair. There is no tendency for genes arising from one parent to stay together. Of course, we now know that this latter principle is true only for unlinked genes. Genes or loci that are linked, or physically located in close proximity on the same chromosome, do not assort independently. The closer these loci are, the more frequently they will cosegregate. Linkage analysis is a quantitative measurement of this cosegregation (expressed as a LOD score or \log_{10} of the odds ratio for cosegregation vs. independent assortment)⁴ and has been a powerful tool in human genetics to map genes for disease traits to particular regions in the human genome.

Chromosomes and Genes

The chromosomal theory of heredity expounded by Walter Sutton emphasized that the diploid chromosome group consists of a morphologically similar set, a homolog pair, for each chromosome and that during meiosis every gamete receives only one chromosome of each homolog pair. This observation was used to explain Mendel's results by assuming that genes, or factors, were part of the chromosome. Genes are arranged in a linear order on the chromosome, each having a specific position or locus. There are two copies for each gene at a given locus, one on each chromosome homolog. These two copies, or alleles, may be identical, or homozygous, at the specific autosomal locus. Alternatively, the two gene copies at a particular locus may be different and represent heterozygous alleles. When only one copy is physically present, either because of deletion of a specific genomic region on the other homolog or because of the special circumstances of the X chromosome in XY males, this condition is referred to as hemizygous. The genes are passed to the next generation through parental gametes, which contain only one of the two alternative gene copies. A particular gamete may contain alleles from different chromosome homologs because of chromosome crossover and recombination of alleles that occur during meiosis.

Mendelian Inheritance

Mendelian inheritance refers to an inheritance pattern that follows the laws of segregation and independent assortment in which a gene inherited from either parent segregates into gametes at an equal frequency. Three major patterns of Mendelian inheritance for disease traits are described: autosomal dominant, autosomal recessive, and X-linked (Figure 1.1). Mendelian inheritance patterns refer to observable traits, not to genes. Some alleles at a specific locus may encode a trait that segregates in a dominant manner, whereas another allele may encode the same or a similar trait, but instead it segregates in a recessive manner.

Autosomal dominant alleles exert their effect despite the presence of a corresponding normal allele on the homologous chromosome. A vertical transmission pattern is observed in the pedigree, with the trait manifested in approximately half of the individuals in each generation (Figure 1.1A). An affected individual will have a 50% chance of transmitting the disease to each independent offspring, which is a reflection of whether a mutant or a normal allele is segregated in the gamete involved in fertilization. Usually, unaffected members of the family do not carry the mutant allele; thus they cannot transmit a disease allele to the next generation. If an affected male transmits the disease to his son, this is considered proof of autosomal dominant inheritance. Male-to-male transmission is inconsistent with X-linked inheritance because a father contributes the Y chromosome but no X chromosome to all his sons.

In autosomal recessive inheritance, both alleles must be abnormal for the disease trait to be expressed. The unaffected parents of an affected child are obligate heterozygote carriers for the recessive mutant allele. Affected children may be homozygous for a specific recessive mutant allele, as is more commonly observed with consanguineous matings, or they may be compound heterozygotes for two different mutations. Couples who are heterozygous carriers of a recessive mutant allele have a 25% risk of having an affected child with each pregnancy. The pattern of transmission observed in the pedigree is horizontal, with multiple members of one generation affected (Figure 1.1B). The unaffected siblings have a 67% (two-thirds) chance of being a carrier for the mutant allele.